Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Total Liabilities: 2012-2024

Historic Total Liabilities for Ocular Therapeutix (OCUL) over the last 13 years, with Dec 2024 value amounting to $142.6 million.

  • Ocular Therapeutix's Total Liabilities rose 10.34% to $152.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.7 million, marking a year-over-year increase of 10.34%. This contributed to the annual value of $142.6 million for FY2024, which is 11.40% down from last year.
  • As of FY2024, Ocular Therapeutix's Total Liabilities stood at $142.6 million, which was down 11.40% from $160.9 million recorded in FY2023.
  • Over the past 5 years, Ocular Therapeutix's Total Liabilities peaked at $185.8 million during FY2020, and registered a low of $113.9 million during FY2022.
  • Moreover, its 3-year median value for Total Liabilities was $142.6 million (2024), whereas its average is $139.1 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first skyrocketed by 125.53% in 2020, then plummeted by 37.08% in 2021.
  • Yearly analysis of 5 years shows Ocular Therapeutix's Total Liabilities stood at $185.8 million in 2020, then plummeted by 37.08% to $116.9 million in 2021, then declined by 2.55% to $113.9 million in 2022, then surged by 41.28% to $160.9 million in 2023, then declined by 11.40% to $142.6 million in 2024.